Key Insights on Gross Profit: Ligand Pharmaceuticals Incorporated vs MiMedx Group, Inc.

Pharma Giants' Profit Battle: Ligand vs. MiMedx

__timestampLigand Pharmaceuticals IncorporatedMiMedx Group, Inc.
Wednesday, January 1, 201455402000105558000
Thursday, January 1, 201566107000167094000
Friday, January 1, 2016103402000212608000
Sunday, January 1, 2017135736000285920000
Monday, January 1, 2018245116000322725000
Tuesday, January 1, 2019108935000256174000
Wednesday, January 1, 2020156000000208904000
Friday, January 1, 2021214957000215332000
Saturday, January 1, 2022143418000219525000
Sunday, January 1, 202396265000266843000
Loading chart...

In pursuit of knowledge

A Decade of Gross Profit Trends: Ligand Pharmaceuticals vs. MiMedx Group

In the competitive landscape of pharmaceuticals, understanding financial performance is crucial. Over the past decade, Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc. have showcased intriguing trends in their gross profits. From 2014 to 2023, MiMedx consistently outperformed Ligand, with an average gross profit approximately 70% higher. Notably, MiMedx peaked in 2018 with a gross profit of over $320 million, while Ligand's highest was in the same year, reaching around $245 million. However, Ligand's growth trajectory was more volatile, with a significant dip in 2023, dropping to about $96 million. This data highlights the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to substantial financial shifts. Investors and analysts should consider these trends when evaluating potential opportunities in the sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025